Literature DB >> 12036941

Splice variants but not mutations of DNA polymerase beta are common in bladder cancer.

Tracy E Thompson1, Peter K Rogan, John I Risinger, Jack A Taylor.   

Abstract

DNA polymerase beta (POLbeta) is a highly conserved protein that functions in base excision repair. Loss of the POLbeta locus on chromosome 8p is a frequent event in bladder cancer, and loss of POLbeta function could hinder DNA repair leading to a mutator phenotype. Both point mutations and large intragenic deletions of POLbeta have been reported from analysis of various tumor cDNAs but not from genomic DNA. We noticed that the breakpoints of the presumed rearrangements were delineated by exon-exon junctions, which could instead be consistent with alternative splicing of POLbeta mRNA. We tested the hypothesis that the reported intragenic deletion were splice variants by screening genomic DNA of human bladder tumors, bladder cancer cell lines, and normal bladder tissues for mutations or deletions in exons 1-14, exon alpha, and the promoter region of POLbeta. We found no evidence of somatic mutations or deletions in our sample set, although two polymorphisms were identified. Examination of cDNA from a subset of the original sample set revealed that truncated forms of POLbeta were surprisingly common. Forty-eight of 89 (54%) sequenced cDNA clones had large deletions, each beginning and/or ending exactly at exon-exon junctions. Because these deletions occur at exon-exon junctions and are seen in cDNA but not genomic DNA, they are consistent with alternative mRNA splicing. We describe 12 different splicing events occurring in 18 different combinations. Loss of exon 2 was the most frequent, being found in 42 of 49 (86%) of the variant sequenced clones. The splice variants appear to be somewhat more common and variable in bladder cancer cell lines and tumor tissues but occur at a high frequency in normal bladder tissues as well. We examine alternative splicing in terms of the information content of splice donor and acceptor site sequences, and discuss possible explanations for the predominant splicing event, the loss of exon 2.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036941

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Characterization of DNA polymerase beta splicing variants in gastric cancer: the most frequent exon 2-deleted isoform is a non-coding RNA.

Authors:  Valeria Simonelli; Mariarosaria D'Errico; Domenico Palli; Rajendra Prasad; Samuel H Wilson; Eugenia Dogliotti
Journal:  Mutat Res       Date:  2009-07-25       Impact factor: 2.433

2.  Mutation of DNA polymerase beta in esophageal carcinoma of different regions.

Authors:  Guo-Qiang Zhao; Tao Wang; Qin Zhao; Hong-Yan Yang; Xiao-Hui Tan; Zi-Ming Dong
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

Review 3.  Normal and abnormal mechanisms of gene splicing and relevance to inherited skin diseases.

Authors:  Vesarat Wessagowit; Vijay K Nalla; Peter K Rogan; John A McGrath
Journal:  J Dermatol Sci       Date:  2005-07-27       Impact factor: 4.563

4.  A survey of splice variants of the human hypoxanthine phosphoribosyl transferase and DNA polymerase beta genes: products of alternative or aberrant splicing?

Authors:  Adonis Skandalis; Elke Uribe
Journal:  Nucleic Acids Res       Date:  2004-12-15       Impact factor: 16.971

Review 5.  Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.

Authors:  Jörn Lötsch; Carsten Skarke; Jürgen Liefhold; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  The human XPC DNA repair gene: arrangement, splice site information content and influence of a single nucleotide polymorphism in a splice acceptor site on alternative splicing and function.

Authors:  Sikandar G Khan; Vanessa Muniz-Medina; Tala Shahlavi; Carl C Baker; Hiroki Inui; Takahiro Ueda; Steffen Emmert; Thomas D Schneider; Kenneth H Kraemer
Journal:  Nucleic Acids Res       Date:  2002-08-15       Impact factor: 16.971

Review 7.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

8.  RNA aptamers selected against DNA polymerase beta inhibit the polymerase activities of DNA polymerases beta and kappa.

Authors:  Leonid V Gening; Svetlana A Klincheva; Anastasia Reshetnjak; Arthur P Grollman; Holly Miller
Journal:  Nucleic Acids Res       Date:  2006-05-17       Impact factor: 16.971

9.  The Pol β variant containing exon α is deficient in DNA polymerase but has full dRP lyase activity.

Authors:  Da-Peng Dai; Rajendra Prasad; Phyllis R Strauss; Samuel H Wilson
Journal:  Sci Rep       Date:  2019-07-09       Impact factor: 4.379

10.  Genome-Wide Analyses of Prognostic and Therapeutic Alternative Splicing Signatures in Bladder Urothelial Carcinoma.

Authors:  Zhongru Fan; Zhe Zhang; Chiyuan Piao; Zhuona Liu; Zeshu Wang; Chuize Kong
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.